Scarica l'app Stockscreener
8.39
0.24%
0.02
Dopo l'orario di chiusura:
8.26
-0.13
-1.55%
Precedente Chiudi:
$8.37
Aprire:
$8.43
Volume 24 ore:
1.42M
Relative Volume:
1.37
Capitalizzazione di mercato:
$626.58M
Reddito:
-
Utile/perdita netta:
$-27.03M
Rapporto P/E:
-14.98
EPS:
-0.56
Flusso di cassa netto:
$-23.97M
1 W Prestazione:
-1.99%
1M Prestazione:
-4.33%
6M Prestazione:
+100.24%
1 anno Prestazione:
+13.69%
Intervallo 1D:
$8.20
$8.555
Intervallo di 1 settimana:
$8.20
$9.205
Portata 52W:
$2.54
$9.60
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Nome
Corvus Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 900-4520
Indirizzo
863 MITTEN ROAD, BURLINGAME, CA
Confronta CRVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
8.39 | 625.09M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-01-02 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-18 | Iniziato | Oppenheimer | Outperform |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-05-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Downgrade | Mizuho | Buy → Neutral |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-05-29 | Iniziato | ROTH Capital | Buy |
| 2017-08-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Iniziato | Credit Suisse | Outperform |
| 2016-04-18 | Iniziato | Guggenheim | Buy |
Mostra tutto
Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie
Corvus Pharmaceuticals stock awaits key January 2026 trial data By Investing.com - Investing.com Canada
Is Corvus Pharmaceuticals Inc a good long term investmentMarket Depth Overview & Budget Friendly Stock Tips - earlytimes.in
What is Corvus Pharmaceuticals Inc (CRVS) Stock Return on Shareholders’ Capital? - setenews.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.1% HigherWhat's Next? - MarketBeat
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Corvus Pharmaceuticals Reports Promising Phase 1 Data for Soquelitinib in Relapsed/Refractory T Cell Lymphoma at ASH Annual Meeting - Quiver Quantitative
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial - Yahoo Finance
Corvus Pharma (CRVS) Stock Analysis Report | Financials & Insights - Benzinga
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month HighHere's What Happened - MarketBeat
You might want to take a look at Corvus Pharmaceuticals Inc (CRVS) now - setenews.com
Will Corvus Pharmaceuticals Inc. stock split again soonMarket Performance Report & Growth Focused Investment Plans - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8%Here's What Happened - MarketBeat
Here's Why We're Not Too Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation - Yahoo Finance
Is Corvus Pharmaceuticals Inc. stock a buy before product launchesDividend Hike & Intraday High Probability Alerts - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Perhaps timely catching Corvus Pharmaceuticals Inc (CRVS) would be a good idea - Setenews
Foresite Capital Management VI LLC Boosts Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals: Trial Momentum Keeps Stock In Focus - RTTNews
What risks investors should watch in Corvus Pharmaceuticals Inc. stockWeekly Trend Summary & Weekly Watchlist for Consistent Profits - newser.com
Will Corvus Pharmaceuticals Inc. stock reach Wall Street targetsPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
Is Corvus Pharmaceuticals Inc. stock affected by interest rate hikes2025 Geopolitical Influence & Consistent Profit Trading Strategies - newser.com
Is Corvus Pharmaceuticals Inc. stock supported by innovation pipeline2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
What valuation multiples suggest for Corvus Pharmaceuticals Inc. stockRecession Risk & AI Forecast Swing Trade Picks - newser.com
Corvus Pharmaceuticals Inc. stock momentum explainedWeekly Profit Report & Verified Swing Trading Watchlist - newser.com
Its Stock Has Paid Off Big Time For Corvus Pharmaceuticals Inc - Setenews
BML Capital Management LLC Buys New Stake in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals Inc. recovery potential after sell offPortfolio Update Summary & Safe Capital Growth Tips - newser.com
Using RSI to spot recovery in Corvus Pharmaceuticals Inc.Earnings Growth Report & Long-Term Growth Portfolio Plans - newser.com
Combining price and volume data for Corvus Pharmaceuticals Inc.July 2025 Decliners & Reliable Momentum Entry Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a bottoming baseTrade Risk Summary & Fast Moving Stock Watchlists - newser.com
What drives Corvus Pharmaceuticals Inc stock priceEarnings Miss Alerts & Free Wealth Planning Blueprints - earlytimes.in
Published on: 2025-11-28 13:27:18 - earlytimes.in
What machine learning models say about Corvus Pharmaceuticals Inc.Weekly Profit Analysis & Reliable Breakout Stock Forecasts - newser.com
How to build a dashboard for Corvus Pharmaceuticals Inc. stockJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
Is Corvus Pharmaceuticals Inc. stock a defensive play in 2025July 2025 Recap & Long-Term Safe Investment Ideas - newser.com
Should you wait for a breakout in Corvus Pharmaceuticals Inc.Index Update & Safe Entry Zone Tips - newser.com
Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):